PTSD and concerns about prescription opioids call for coordinated trauma, pain, and prescribing care. The presence of an opioid prescription does not establish an opioid use disorder. Physical dependence can occur during treatment, and pain remains a clinical concern even when medication use has become problematic. A useful assessment asks what each condition is doing, how the treatments interact, and who will coordinate the plan.

Do not abruptly stop or change a long-term opioid prescription without medical advice. The CDC warns that sudden discontinuation or rapid reduction can cause serious harm, including withdrawal, uncontrolled pain, and psychological distress. Difficulty breathing, inability to wake normally, suspected overdose, or immediate danger of self-harm requires emergency help. This guide prepares questions for clinicians; it does not provide opioid dosing or taper instructions.

Begin with three histories, then connect them

Describe the trauma-related symptoms, the pain condition, and the medication history separately before looking at their overlap. When did each begin? What was the medicine intended to treat? Which activities became harder, and which treatments helped? This prevents a single label from replacing the assessment of several real concerns.

The VA National Center for PTSD explains that chronic pain and PTSD can interact, including through avoidance, sleep difficulties, and heightened attention to threat or discomfort. These interactions do not mean the pain is imaginary. They help explain why the care plan may need to address both physical functioning and trauma-related distress rather than asking one treatment to solve every problem.

Bring relevant records from the pain clinician, primary care team, and mental health service if available. A short summary is often easier to use than an unsorted collection. Include the current treatment goals and what remains unresolved. If records describe the situation differently, ask the clinicians to reconcile the differences instead of assuming you must choose which account is correct.

Clarify what concern about opioids actually means

Someone may be worried about needing medication for a long time, taking more than prescribed, becoming unwell after missed doses, or feeling that the medicine no longer provides meaningful benefit. These are different concerns. Explain the specific pattern rather than relying on the word dependent to communicate everything. The clinician can assess physical dependence, treatment benefit, adverse effects, and possible opioid use disorder.

Describe actual use, including extra doses, early refills, missed doses, borrowed medication, or obtaining products outside regular prescribing. Include alcohol, benzodiazepines, sleep medicines, and other substances. Accurate information is essential for safety and should be received without dismissing the underlying pain or trauma symptoms. Ask how the service handles disclosure and what the next assessment will involve.

If a use disorder is diagnosed, request an explanation of the evidence and available treatment. If it is not diagnosed, ask how prescribing concerns will still be addressed. A person should not have to meet a particular label before a clinician discusses side effects, function, continuity, or worries about medication. Our assessment results guide offers questions for that conversation.

Make pain goals specific enough to review

Ask what the pain treatment is intended to improve. A meaningful goal may involve walking to a nearby shop, sitting through a meal, returning to a valued activity, or managing a work task. Pain intensity matters, but it is not the only outcome. Discuss function, sleep, adverse effects, and quality of life alongside symptom ratings.

The VA’s chronic pain and PTSD guidance describes coordinated approaches that can include psychological treatment and rehabilitation-oriented care. Ask which options are suitable for the assessed pain condition and how they fit with PTSD treatment. A referral to therapy should not be presented as proof that medical assessment is unnecessary; it can be one part of a broader plan.

Tell the team about activities avoided because they trigger both pain and trauma-related fear. For example, a crowded exercise setting may raise different barriers from an individual session. The clinician can help distinguish physical restrictions from fear-based avoidance and adapt the plan appropriately. Do not push through an activity against medical advice simply because avoidance is being discussed.

Keep PTSD treatment visible in the plan

Ask what treatment is proposed for PTSD, who will provide it, and how readiness and current safety will be assessed. The VA’s guidance on co-occurring PTSD and substance use disorders supports evidence-based treatment for both concerns. A substance-related problem does not automatically mean PTSD care must be postponed indefinitely until every other issue is resolved.

At the same time, acute intoxication, a crisis, or another unstable medical situation may require immediate attention before particular therapy work. Ask for a specific explanation of the priority and the next review point. A temporary clinical sequence should have a purpose; it should not become an open-ended requirement with no route back to treatment.

If therapy increases distress between sessions, report what happens and ask how support will be adjusted. Do not make independent medication changes to manage the session’s effects. The therapist and prescriber should understand the pattern, with your consent, so they can respond together. The shared care plan guide describes how responsibilities and communication can be documented.

Review prescribing without abandoning the person

The CDC’s opioid prescribing guideline emphasizes that opioid reduction should be individualized when clinically indicated, with appropriate care and monitoring. It warns against abrupt discontinuation in physically dependent patients. If a change is proposed, ask why, what alternatives were considered, how pain and withdrawal-related concerns will be addressed, and who will be available for review.

Do not assume that a standard taper advertised by a program is appropriate for your history. The length of a residential stay, an insurance authorization, or a clinician’s upcoming absence should not be treated as a patient-designed medication schedule. Ask the responsible prescriber how continuity will be maintained if the process extends beyond the current treatment episode.

If the current prescriber will no longer manage the medication, request a clear transition plan. Who has accepted the referral, what information has been shared, and when will the next assessment occur? A name on a list of possible clinics is not the same as a completed handoff. Practical access needs to be resolved alongside the clinical recommendation.

If opioid use disorder treatment is needed

Ask a qualified clinician about evidence-based treatment options and how they can coexist with pain and PTSD care. Medication for opioid use disorder has a different treatment purpose from an opioid prescribed solely for pain, although the clinical plan may need to account for both. Avoid making changes based on assumptions that every opioid-containing medicine serves the same role.

The CDC advises that buprenorphine and methadone for opioid addiction should not automatically be withheld because a person also uses benzodiazepines or other central nervous system depressants. The combination can be risky and needs careful management, while untreated opioid addiction also creates serious harm. This is a reason for coordinated clinical care, not reassurance that combining substances without supervision is safe.

Ask how the service handles ongoing medication when someone enters residential trauma or addiction treatment. Confirm the policy with a clinician before admission. If a program cannot provide appropriate continuation or coordination, discuss alternatives with the treating team rather than stopping effective treatment to fit a program rule. The person should understand the clinical implications of any proposed change.

Make safety planning practical and individualized

Discuss overdose risk, medication storage, and whether naloxone should be available with the prescribing or addiction clinician. Ask for clear instructions appropriate to the person’s situation and household. If overdose is suspected, call emergency services immediately and follow emergency guidance. Do not leave an unresponsive person to sleep or assume that familiar medication cannot be involved in a serious event.

Include psychological safety. Pain, trauma symptoms, and fear about medication changes can be distressing. Tell the clinician about hopelessness, thoughts of self-harm, or feeling unable to cope. A plan should identify an urgent contact route and a response to worsening symptoms. Immediate danger requires emergency help rather than waiting for the next routine review.

Agree how a trusted person may help, if you want them involved. Their role might include transport, attending a planning meeting, or helping communicate concerns. They should not be expected to decide doses, negotiate between clinicians, or take sole responsibility for a crisis. The support arrangement should be realistic and respectful of everyone involved.

Use follow-up to judge the whole plan

At review, discuss pain, function, PTSD symptoms, medication use, adverse effects, and access to care together. Improvement in one area can coexist with difficulty in another. Ask what the team will change if the plan is not producing the intended results. A clear process for adjustment is more useful than a promise that a single intervention will resolve all three concerns.

Before the consultation ends, identify the next action for pain care, trauma treatment, and prescribing. Name the responsible professional and the review date for each. NIMH’s co-occurring disorders guidance supports considering mental health and substance use together. For this particular situation, that principle becomes concrete when no part of the plan is left without an owner or a route for follow-up.

Sources and further reading

Found a detail that has changed? Tell the editorial team.